Four Drug Names, Two Active Ingredients, and a Lot of Confusion
With 2.5 million views, this video from Ohio State Wexner Medical Center clearly answers a question that millions of people are asking: what is the difference between Ozempic, Mounjaro, Wegovy, and Zepbound? Who qualifies for which one? And does it matter which you take? The confusion is understandable because the naming and marketing of these drugs is genuinely confusing, and even some healthcare providers mix up the indications and eligibility criteria. This write-up breaks down the practical differences so you can have a more informed conversation with your doctor.
Let us start with the basics. There are two active ingredients across these four brand names. Semaglutide is the active ingredient in both Ozempic and Wegovy. Tirzepatide is the active ingredient in both Mounjaro and Zepbound. The difference between Ozempic and Wegovy is not the molecule. It is the indication. Ozempic is FDA-approved for type 2 diabetes. Wegovy is FDA-approved for chronic weight management. The exact same drug, the exact same manufacturer (Novo Nordisk), but different brand names, different packaging, different dosing ranges, and different insurance coverage pathways. The same pattern applies to Mounjaro (approved for type 2 diabetes) and Zepbound (approved for weight management), both made by Eli Lilly.
This dual-branding strategy exists for regulatory and commercial reasons. Getting FDA approval for a new indication requires a separate set of clinical trials. Novo Nordisk ran the STEP trials to prove semaglutide worked for weight management and received approval to sell it under the Wegovy brand at higher doses than Ozempic typically uses. Eli Lilly did the same with the SURMOUNT trials for tirzepatide. The result is four brand names that patients and doctors must navigate, each with its own set of rules around prescribing, coverage, and availability.
Semaglutide: Ozempic and Wegovy
Semaglutide is a GLP-1 receptor agonist. It mimics a natural hormone called glucagon-like peptide-1 that your gut releases after eating. GLP-1 does several things: it stimulates insulin release, suppresses glucagon (a hormone that raises blood sugar), slows gastric emptying (so food stays in your stomach longer and you feel full longer), and acts on appetite centers in the brain to reduce hunger and cravings. Semaglutide is a modified version of human GLP-1 that lasts much longer in the body, allowing once-weekly dosing instead of the minutes-long half-life of natural GLP-1.
Ozempic is prescribed for adults with type 2 diabetes to improve blood sugar control. The typical dose range is 0.25 mg to 1 mg weekly, with a 2 mg dose available for patients who need additional glycemic control. Weight loss occurs as a side effect, often a welcome one, but it is not the primary purpose of the prescription. Insurance coverage for Ozempic is generally good for patients with a type 2 diabetes diagnosis because it is an FDA-approved diabetes medication.
Wegovy is prescribed for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity (high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea). The dosing for Wegovy goes higher than Ozempic, reaching 2.4 mg weekly after a gradual titration schedule. Insurance coverage for Wegovy is inconsistent. Many insurance plans explicitly exclude weight management medications, and even plans that cover Wegovy may require prior authorization showing that the patient has tried and failed lifestyle interventions first.
Wegovy was also approved in 2024 for cardiovascular risk reduction in adults with obesity and established cardiovascular disease, based on data from the SELECT trial. This additional indication may improve insurance coverage for some patients because it reframes the drug as a cardiovascular medication rather than purely a weight loss drug. It is worth asking your insurer whether the cardiovascular indication changes your coverage status if you have been denied under the weight management indication.
Tirzepatide: Mounjaro and Zepbound
Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two hormone receptors instead of one. GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone that works alongside GLP-1 to regulate blood sugar, appetite, and metabolism. The dual mechanism appears to produce greater weight loss on average compared to semaglutide, though head-to-head comparison data is limited and the difference may not be clinically significant for every individual patient.
Mounjaro is approved for type 2 diabetes and is available in doses from 2.5 mg to 15 mg weekly. Like Ozempic, it produces significant weight loss alongside blood sugar improvement, and insurance coverage is generally favorable for patients with a diabetes diagnosis. Zepbound is approved for chronic weight management with the same BMI criteria as Wegovy (BMI 30+ or BMI 27+ with comorbidities). Zepbound doses range from 2.5 mg to 15 mg weekly.
In the SURMOUNT-1 trial, tirzepatide at the highest dose (15 mg) produced an average weight loss of about 22.5% of body weight after 72 weeks. That is more than what semaglutide 2.4 mg achieved in the STEP 1 trial (about 15%), though the trials had different patient populations and direct comparison requires caution. A head-to-head trial comparing semaglutide and tirzepatide directly (the SURPASS-SWITCH study for diabetes) showed tirzepatide had a slight edge in blood sugar reduction, but a definitive weight loss head-to-head has not been published.
Zepbound also received FDA approval in late 2024 for moderate to severe obstructive sleep apnea in adults with obesity, making it the first pharmaceutical treatment for that condition. This additional indication opens another pathway for insurance coverage and medical justification beyond weight management alone.
Who Qualifies for What
This is where the practical rubber meets the road, and the Ohio State team lays it out clearly. If you have type 2 diabetes, you may qualify for either Ozempic or Mounjaro. Your doctor will choose based on your blood sugar targets, insurance coverage, and individual response. Many patients start with Ozempic because it has a longer track record, then switch to Mounjaro if they need more aggressive blood sugar or weight control.
If you do not have type 2 diabetes but have obesity (BMI 30+), you may qualify for Wegovy or Zepbound. You may also qualify with a BMI of 27 or higher if you have a weight-related comorbidity. Getting insurance to cover these medications is the primary challenge for most patients. Prior authorization requirements vary by plan, and some plans exclude weight management drugs entirely.
There are some situations where doctors prescribe Ozempic or Mounjaro off-label for weight loss in patients without diabetes. This is legal (doctors can prescribe any FDA-approved drug for any indication they consider medically appropriate), but insurance is unlikely to cover an off-label prescription for a non-diabetes patient. The cost out of pocket ranges from $800 to $1,500 per month for branded products, which puts them out of reach for many patients without coverage.
The Ohio State video also addresses special populations. Pregnant or breastfeeding women should not use any of these medications. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use GLP-1 receptor agonists because of a theoretical thyroid tumor risk identified in rodent studies. Patients with a history of pancreatitis should discuss the risk with their doctor, as GLP-1 drugs have been associated with a small increase in pancreatitis risk in some studies.
Choosing Between Semaglutide and Tirzepatide
For patients who qualify for both options, the choice between semaglutide and tirzepatide often comes down to several practical factors. Insurance coverage and out-of-pocket cost are typically the most decisive. If your insurance covers one but not the other, that usually settles the question. If both are covered, or if you are paying out of pocket, the clinical differences become more relevant.
Tirzepatide tends to produce slightly more weight loss on average, which may matter for patients with severe obesity or those who have not achieved adequate results on semaglutide. Semaglutide has a longer track record and more published data on cardiovascular outcomes (the SELECT trial), which may be relevant for patients with established heart disease. Side effect profiles are similar between the two, with gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation) being the most common for both. Some patients tolerate one better than the other for reasons that are difficult to predict in advance.
Availability fluctuates. Both drugs have experienced supply shortages at various points, and the situation changes month to month. Your prescriber and pharmacy can usually tell you which products are currently in stock. Being flexible about which brand you use, within the appropriate drug class for your indication, increases your chances of actually getting the medication rather than sitting on a waitlist.
What to Discuss With Your Doctor
Come to the appointment prepared with a few key pieces of information. Know your current BMI. Know your insurance plan's formulary (the list of covered medications) or at least be willing to call your insurer before the appointment. If you have a type 2 diabetes diagnosis, that changes your options significantly. If you have comorbidities like high blood pressure, sleep apnea, cardiovascular disease, or fatty liver, mention them specifically because they affect eligibility and may improve insurance authorization.
Ask your doctor which medication they think is the best fit for your specific situation and why. Ask about the titration schedule (all of these drugs start at a low dose and increase gradually). Ask about expected side effects during dose escalation and what you can do to manage them. Ask about the monitoring plan: how often will you follow up, what labs will be checked, and what benchmarks will be used to evaluate whether the medication is working.
Finally, ask about the long-term plan. These medications work while you take them. Stopping without a transition plan is associated with weight regain. Understanding from the beginning whether the plan involves indefinite use, eventual tapering, or transition to lifestyle maintenance will help you set realistic expectations and prepare accordingly. The medication is a tool. How effectively you use it depends on the plan surrounding it.